Business
OncBioMune Provides Corporate Update, Nearly 50 Drug Candidates in Pipeline or Being Negotiated
OncBioMune Provides Corporate Update, Nearly 50 Drug Candidates in Pipeline or Being Negotiated.
About this update from Theralink Technologies Inc.
[{"type":"text","content":"\nOncBioMune Provides Corporate Update, Nearly 50 Drug Candidates in Pipeline or Being Negotiated\n\nOncBioMune Provides Corporate Update, Nearly 50 Drug Candidates in Pipeline or Being Negotiated\n\nBATON ROUGE, LA--(Marketwired - May 09, 2017) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) (\"OncBioMune\" or the \"Company\"), a clinical stage biopharmaceutical company engaged in the development of targeted cancer therapies and a proprietary vaccine technology, is pleased to provide a corporate update on corporate and clinical developments thus far in the first half of 2017.When OncBioMune chose to enter the public markets in late in September 2015, management was charged with two primary directives to build shareholder value. One was to advance ProscaVax through a phase 1 study into mid-stage trials with the ultimate goal of late-stage research and commercialization as the world's first therapeutic prostate cancer vaccine. The second was to employ an aggressive acquisition strategy for a variety of purposes, including generating revenue to fund R&D activity and additional acquisitions. Approximately one and a half year later, the Company continues to effectively execute on this business model. Since the start of 2017, OncBioMune has announced:Completing the acquisition of Vitel Laboratorios S.A. de C.V. (\"Vitel\"), establishing OncBioMune Mexico S.A. de C.V. as a wholly-owned Mexico City-based subsidiary of OncBioMune as it integrates Vitel's operations into a component of the Company. The acquisition transitioned OncBioMune into a revenue-generating company with two recently commercialized drugs and a portfolio of others either already licensed or in negotiations for licensing or acquisition.Sales in Mexico from September 16, 2016 to April 17, 2017 for Bekunis® for constipation and Cirkused® for stress were approximately US$350,000, exceeding projections for US$155,000 initially forecast for the first seven months at product launch during the third quarter of 2016. The Company anticipates that sales efforts will continue to accelerate and anticipates combined sales in the range of US$750,000 to US$850,000 for the products in 2017.Completing enrollment in the Phase 1 study of ProscaVax evaluating the novel therapeutic cancer vaccine in the treatment of prostate specific antigen (PSA) recurrent prostate cancer ...